| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | 0 | 0 | 4.944 | 47.907 | 102.943 | 86.139 | 87.192 | 102.893 |
| Total Income - EUR | - | - | 0 | 10.219 | 6.612 | 50.341 | 105.323 | 88.328 | 89.573 | 105.284 |
| Total Expenses - EUR | - | - | 0 | 15.957 | 22.104 | 47.379 | 85.377 | 81.884 | 84.533 | 105.064 |
| Gross Profit/Loss - EUR | - | - | 0 | -5.739 | -15.492 | 2.962 | 19.946 | 6.445 | 5.039 | 220 |
| Net Profit/Loss - EUR | - | - | 0 | -5.739 | -15.540 | 2.501 | 18.938 | 5.713 | 4.298 | 186 |
| Employees | - | - | 0 | 3 | 3 | 3 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Novoclinique Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | 0 | 32.664 | 38.657 | 43.141 | 39.347 | 34.797 | 28.634 | 22.451 |
| Current Assets | - | - | 43.826 | 2.955 | 5.285 | 583 | 490 | 3.916 | 3.258 | 3.488 |
| Inventories | - | - | 0 | 2.559 | 5.017 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | 43.782 | 0 | 178 | 89 | 0 | 3.430 | 2.485 | 170 |
| Cash | - | - | 44 | 395 | 89 | 493 | 490 | 486 | 773 | 3.318 |
| Shareholders Funds | - | - | 44 | -5.696 | -21.126 | -18.224 | 1.117 | 6.834 | 11.111 | 11.234 |
| Social Capital | - | - | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | 0 | 25.652 | 55.386 | 43.224 | 22.792 | 18.091 | 9.415 | 5.770 |
| Income in Advance | - | - | 43.782 | 23.694 | 21.567 | 18.724 | 15.928 | 13.789 | 11.366 | 8.936 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8690 - 8690" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Novoclinique Srl